Interactive Brokers Advertisement
Home > Boards > US Listed > Cannabis >

Zynerba Pharmaceuticals (ZYNE)

Add ZYNE Price Alert      Hide Sticky   Hide Intro
Moderator: Cbdpotential, djmurdock
Search This Board: 
Last Post: 6/22/2017 1:47:18 PM - Followers: 50 - Board type: Free - Posts Today: 0

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Investor Relations

Corporate Profile

Zynerba (NASDAQ: ZYNE) is pioneering the development of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In June 2016, the company initiated the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in August 2016, initiated the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. A Phase 2 clinical trial in patients with Fragile X syndrome will be initiated in the second half of 2016. 

ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in preclinical development. A Phase 1 clinical trial is planned in the first half of 2017.

In August 2015, Zynerba completed an initial public offering, raising net proceeds of $42.1 million. As of June 30, 2016, cash and cash equivalents totaled $32.1 million, which is projected to fund five Phase 2 clinical trials through 2017.

Zynerba Pharmaceuticals, Inc., (Nasdaq: ZYNE) announced today the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. In addition, Zynerba has granted the underwriters an option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discount. Zynerba's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the symbol "ZYNE" on August 5, 2015.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. This offering is being made only by means of a prospectus.

Extremely low float:


A table providing the fundamentals of the stock
EPS (TTM) 9/30/2016 | -2.47
P/E Ratio 9/30/2016 | --
Market Cap Micro Cap | 146M
Shares Outstanding 9.95M
Float 7.2M


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ZYNE News: Notice of Effectiveness (effect) 06:02 AM
ZYNE News: Notice of Effectiveness (effect) 06/16/2017 06:01:02 AM
ZYNE News: Statement of Changes in Beneficial Ownership (4) 06/09/2017 05:15:26 PM
ZYNE News: Statement of Changes in Beneficial Ownership (4) 06/09/2017 05:14:58 PM
ZYNE News: Statement of Changes in Beneficial Ownership (4) 06/09/2017 05:14:32 PM
News News Alert: Notice of Effectiveness (effect) 06/23/2017 06:02:29 AM
#326  Sticky Note Slideshow for new investors djmurdock 12/17/16 05:09:50 PM
#629   This stock is so easy to manipulate and djmurdock 06/22/17 01:47:18 PM
#628   Yep. All 7 analysts on NASDAQ rate this LoveItInBishop 06/19/17 06:04:19 PM
#627   Nice! Great start to the week, hopefully this djmurdock 06/19/17 02:54:19 PM
#626   So sweet. So much coming out this summer. LoveItInBishop 06/19/17 11:57:41 AM
#625   Let's be honest. It will not go below WolfOfGrnStreet 06/18/17 02:17:03 AM
#624   $ZYNE$- excellent update. Some shorts gonna get toasted surfgreen 06/17/17 12:37:02 PM
#623   Notice of Effectiveness followed by after hours rally LoveItInBishop 06/16/17 11:48:55 PM
#622   New Frontier Data PR on medical cannabis. GLTA OBhands 06/15/17 09:21:45 AM
#621   The manipulative games of this stock are getting djmurdock 06/14/17 03:15:18 PM
#620   A solid move over 20$ would speak volumes here Cbdpotential 06/14/17 09:39:10 AM
#619   it's just 50 shares but still nice to LoveItInBishop 06/14/17 08:57:25 AM
#618   HOLY CRAP!!!! $20 pre mkt. WooHoo $$$$$ LoveItInBishop 06/14/17 08:41:57 AM
#617   Insty ownership up to 26.5% now!!!! djmurdock 06/14/17 12:08:01 AM
#616   ZYNE is here to stay. Next leg coming quick WolfOfGrnStreet 06/13/17 08:50:28 PM
#615   Just a shake. Great things on the horizon $$$$$$ LoveItInBishop 06/13/17 08:11:35 PM
#614   Filings came out Friday, just reorganizing financing. No djmurdock 06/13/17 12:56:26 PM
#613   Hold tight shake n bake surfgreen 06/13/17 10:55:18 AM
#612   Nice bounce. Hopefully it was a true shake TinyGreenSprout 06/13/17 10:18:35 AM
#611   Way oversold. Broke the 200dma so better bounce surfgreen 06/12/17 08:51:08 PM
#610   All tech sector down, so not surprising to CoachMarc 06/12/17 05:07:13 PM
#609   Can anyone rationalize today's drop? I see a TinyGreenSprout 06/12/17 01:18:45 PM
#608   Wow!!!7 analysts rate this a strong buy LoveItInBishop 06/11/17 10:22:34 PM
#607   Things will improve. Thats for sure $$$$$$ LoveItInBishop 06/11/17 02:10:12 PM
#606   Welcome to the club, July or August should djmurdock 06/11/17 01:10:21 PM
#605   got a bunch Fri @ 17.95. Great things LoveItInBishop 06/10/17 02:10:45 PM
#604 djmurdock 06/08/17 06:19:08 PM
#603   $Zyne never fails to deliver. djmurdock 06/08/17 04:57:15 PM
#602   "once we have the data in hand" haha djmurdock 06/05/17 07:13:01 PM
#601 djmurdock 06/05/17 07:08:12 PM
#600   Worldwide osteoarthritis is a huge market. Money in djmurdock 05/31/17 11:34:58 PM
#599   I remember when I first profiled it lol. WolfOfGrnStreet 05/31/17 10:19:51 PM
#598   "global right to both of their lead product djmurdock 05/31/17 05:50:02 PM
#597   Nice HOD close! djmurdock 05/25/17 04:02:22 PM
#596   IMHO yes, major institutions and insiders have been djmurdock 05/25/17 04:02:04 PM
#595   I did Loosingstocks 05/25/17 03:33:08 PM
#594   Good entry point here under 19 huh? MoToM 05/25/17 01:38:21 PM
#593   Here we go. First NEJ publication and buyout surfgreen 05/25/17 09:46:28 AM
#592 djmurdock 05/24/17 12:52:21 PM
#591 djmurdock 05/24/17 12:51:55 PM
#590   Sounds about right. Can't wait for July/Aug djmurdock 05/24/17 12:34:05 PM
#589   Looks like manipulation and loading for summer results. surfgreen 05/24/17 12:28:15 PM
#588   Not hyped on this downtrend. djmurdock 05/24/17 11:35:35 AM
#587   Let's hold this 20$ level and never look back! $zyne Cbdpotential 05/17/17 02:57:31 AM
#586   Put me in Coach!!! (: (: Nice catch, djmurdock 05/16/17 10:08:17 PM
#585   Your right that day the stock was trading RigorousGains 05/16/17 05:57:48 PM
#584   The bought millions @18 a few months back surfgreen 05/16/17 05:56:23 PM
#583   I need couple millions to feel confident at RigorousGains 05/16/17 05:48:43 PM
#582   Agreed! Like everything I see: 5 phase 3's massive surfgreen 05/16/17 03:16:48 PM
#581   More insider purchases at $19.70-80! About $200,000 worth! CoachMarc 05/16/17 02:00:03 PM
#580   It's going to be a fun ride! a surfer 05/16/17 09:21:35 AM